Predictive Oncology & Intervention Strategies
Molecular Basis of Oncogenesis & Cancer Control
February 7 - 10, 2004Hotel WestminsterNice, France

Continuing Medical Education at the 2004 Symposium

CME Credits


This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS). The UMMS is accredited by ACCME to provide continuing medical education for physicians. The UMMS designates this continuing medical education activity for up to 36 credit hours in Category 1 toward the Physicians Recognition Award of the American Medical Association.

Each physician should claim only those hours of credit that he or she actually spent in the educational activity.


This offering meets the requirements for 42 contact hours for nurses as specified by the Massachusetts Board of Registration in nursing. (244-CMR 5.04)

Conflict of interest disclosure

In accordance with the Standards of the ACCME and the guidelines of the AAMC, it is the policy of the UMMS to disclose whatever interest or affiliation a speaker might have with any commercial organization whose products or services are related to the subject matter being presented. Such disclosure will be made available on the day of the program.

Disclaimer: The opinions and recommendations expressed by faculty and other experts whose input is included in this CME activity are their own. This CME activity is produced for educational purposes only.

Educational Objectives

At the conclusion of the program, the participant should have a thorough awareness of the molecular and epidemiologic basis for the following:

  • the current cancer risk assessments of biologically significant exposure to environmental agents which may relate to genetic susceptibility and individual cancer risk prediction
  • the immune responses to chronic inflammation that underlie multistep tumor progression and the biomarkers specific to each of the steps
  • capabilities and implications of the new genomic & proteomic technologies
  • the multifactorial variability of interindividual and interethnic expression of DNA methylation patterns and chromatin structure
  • prevention strategies that translate the understanding of carcinogenic and epigenetic mechanisms into targeted clinical interventions
  • chemopreventive strategies to inhibit, reverse, and monitor malignant and preneoplastic events
  • nutritional modification and cancer risk avoidance health practices
  • screening practice guidelines for the most common cancers and the challenges for screening compliance including public behavior, beliefs, and perceptions about cancer control
  • the public health goals and expectations of the new prevention trials and translational research.